Related Experiment Video

Updated: May 22, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

Genetic polymorphisms influence the steroid treatment of children with idiopathic nephrotic syndrome

Yee-Hsuan Chiou1, Lin-Yu Wang, Tzu-Hui Wang

  • 1Division of Pediatric Nephrology, Department of Pediatrics, Kaohsiung Veterans General Hospital, 386, Ta-Chung 1st Road, Zuoying District, Kaohsiung City, Taiwan. chysn@ms6.hinet.net

Pediatric Nephrology (Berlin, Germany)
|May 22, 2012
PubMed

Insights

The ABCB1 C1236T gene variant is linked to steroid resistance in childhood idiopathic nephrotic syndrome (INS). CYP3A5 A6986G showed a trend, but further research is needed for this genetic marker.

Area of Science:

  • Pediatric Nephrology
  • Pharmacogenetics
  • Molecular Genetics

Background:

  • Idiopathic nephrotic syndrome (INS) is the most common nephrotic syndrome in children.
  • Steroid treatment response in INS varies significantly among pediatric patients.
  • Understanding genetic factors influencing steroid response is crucial for personalized treatment.

Purpose of the Study:

  • To investigate the association between specific gene polymorphisms and steroid treatment response in children with INS.
  • To analyze the correlation between CYP3A5 and ABCB1 gene variants and steroid sensitivity or resistance.

Main Methods:

  • A cohort of 74 children diagnosed with INS was studied.
  • Genetic polymorphisms in CYP3A5 (A6986G) and ABCB1 (C1236T, G2677T/A, C3435T) were analyzed.
  • Genotype frequencies were compared between steroid-sensitive (SS) and steroid-resistant (SR) groups.

Main Results:

  • The ABCB1 C1236T polymorphism was significantly associated with steroid resistance in pediatric INS (OR 2.65, p=0.042).
  • The T allele frequency was higher in steroid-resistant (0.81) versus steroid-sensitive (0.62) children.
  • CYP3A5 A6986G showed a trend towards association with steroid resistance (OR 2.63, p=0.059), but did not reach statistical significance.

Conclusions:

  • The C1236T polymorphism in the ABCB1 gene is a potential genetic marker for steroid resistance in pediatric INS.
  • The CYP3A5 A6986G polymorphism warrants further investigation due to a trend towards association.
  • These findings may contribute to predicting treatment response in children with INS.
Abstract

More Related Videos

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium08:46

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Published on: September 1, 2015

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...